Find Clinical Trials

Inclusion Criteria: * Obstructive sleep apnea patients * obese patients * glaucoma (open angle form with ocular hyoertension) Exclusion Criteria: cardiac patients renal patients hepatic patients

Inclusion Criteria: * Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen. * ≥18 years of age. * Life expectancy \> 6 months * Able to provide informed consent. * Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance. Exclusion Criteria: * Presence of primary brain tumors or brain metastases. * Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy. * Unwilling to undergo neuropsychological assessments necessary for the study. * Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy. * History of or suspected hypersensitivity to riluzole or to any of its excipients. * Patients taking or planned to take medications/substances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole. * Hepatic impairment as indicated by: AST and/or ALT ≥ 3 X upper limit normal (ULN). * Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.

Inclusion Criteria: * women absent of menstruation for over one year, * Chinese, and * fulfill the criteria of elevated/stage I hypertension according to 2025 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (i.e., blood pressure ≥120/80 mmHg based on an average of ≥2 readings obtained on ≥2 occasions) Exclusion Criteria: * presence of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders, * a history of hysterectomy, * current use of vitamin B supplements and/or NAD precursors, * ongoing hormone replacement therapy within the past six months, * any changes in antihypertensive medication type or dosage within the last three months, or * engagement in regular physical activity, defined as at least 150 minutes of moderate-intensity exercise or 75 minutes of vigorous-intensity exercise per week, during the three months prior to enrollment.

Inclusion Criteria: * Active Covered California member * Adult \>= 18 years of age * Has a diabetes and or hypertension diagnosis identifiable in Covered California's administrative claims * Income \<250% FPL Exclusion Criteria: * No longer a Covered California member * $0 spending in year 1 grocery support program

Inclusion Criteria: * Female sex: Older women aged between 60 and 70 years. * Physical capability: Absence of health conditions that could compromise performance in the required physical exercise tests. Exclusion Criteria: * Smoking: Current smokers. * Alcohol use: History of alcohol abuse or excessive alcohol consumption. * Cardiovascular Disease: Diagnosis of cardiovascular diseases (other than the primary condition of hypertension).

Inclusion Criteria: * Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater than or equal to (\>=) 10 percent (%) lung parenchyma with fibrosis) consistent with idiopathic interstitial pneumonia, ILD in association with connective tissue disease, occupational ILD, or chronic hypersensitivity pneumonitis. Chest CTs will be centrally read for eligibility * 40% predicted less than or equal to (\<=) forced vital capacity (FVC) \<= 80% predicted at screening * At least ONE of the following is required to undergo the first screening visit: Documented diagnostic right heart catheterization (RHC) within 18 months of screening with mean pulmonary arterial pressure (mPAP) \>= 25 millimeters of mercury (mm Hg), pulmonary capillary wedge pressure (PCWP) \<=15 mm Hg, and pulmonary vascular resistance (PVR) \>=4 Wood units; Documented echocardiogram (ECHO) within 18 months of screening with right ventricular (RV) (or pulmonary artery) systolic pressure \>46 mm Hg or tricuspid annular plane systolic excursion (TAPSE)/ systolic pulmonary artery pressure (SPAP) \<=0.38 and absence of clinically significant left ventricular dysfunction as assessed by the investigator Exclusion Criteria: * Participants have a confirmed or suspected diagnosis of pulmonary hypertension in World Health Organization (WHO) Group 1, WHO Group 2, WHO Group 4, or WHO Group 5 * Participants have received phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators, intravenous (IV) or subcutaneous (SC) prostacyclin analogues within 30 days before the first screening visit, or sotatercept within 180 days before the first screening visit * Participants have any type of pulmonary and cardiovascular comorbidities as defined n protocol * Participants who are taking disease-modifying therapy for the underlying interstitial lung disease (ILD) (anti-fibrotics, immunosuppressives, and anti-inflammatory medications) who are not on stable doses for \>30 days before the first screening visit or have initiated new ILD-directed therapies within 90 days before the first screening visit

Inclusion Criteria: * Age over 18 years; * Signed informed consent; * in Sinus rhythm; * Patients for whom HOLTER ECG monitoring is clinically indicated, to early identify the possible onset or progression of diabetic autonomic neuropathy, or ischemic changes, or potentially arrhythmogenic electrophysiological alterations; * On optimized pharmacological treatment according to clinical practice, naïve to SGLT2 inhibitor therapy, prescribed according to the (1A) recommendations of the ESC 2023 guidelines. Exclusion Criteria: * Patients with atrial fibrillation or other arrhythmic burden incompatible with accurate HRV analysis; * Pacemaker or ICD carriers; * Immunodeficient patients or patients at risk of developing infections.

Inclusion criteria: * Diagnosis of arterial hypertension and currently taking antihypertensive medication * Age 60 years or older * Resting blood pressure below 160/95 mmHg * No high cardiovascular risk according to the American College of Sports Medicine criteria (for participants with type 2 diabetes, glycemic control with fasting glucose \<100 mg/dL and postprandial glucose \<140 mg/dL) * Not participating in a structured exercise program for more than three months * No cognitive or functional limitations that prevent participation in the exercise program Exclusion Criteria * Presence of acute illnesses, such as influenza, sinusitis, gastroenteritis, urinary tract infection, fever, inflammatory processes, or any clinical condition requiring rest or that may compromise safety during assessments or training. * Decompensated clinical conditions, including: Blood pressure spikes, Chest pain, Uncontrolled arrhythmias, Shortness of breath at rest, Asthma exacerbations, Decompensated diabetes mellitus, characterized by Persistently elevated blood glucose levels (fasting glucose \> 180 mg/dL or postprandial glucose \> 250 mg/dL) * Irregular use of medication * Any unstable clinical condition or condition that represents additional risk for the practice of physical exercise.

Inclusion Criteria: -(1) Age: 5 years ≤ age \< 18 years; (2) 1) Allergic rhinitis caused by Dermatophagoides pteronyssinus and/or Dermatophagoides farinae; 2) Or serum specific IgE ≥ 0.70 (kU/L) (for D. pteronyssinus and/or D. farinae); (3) Children meeting criteria (2) must undergo allergen component testing; (4) If accompanied by bronchial asthma, asthma must be diagnosed according to the Guidelines for the Diagnosis and Prevention of Childhood Bronchial Asthma (2025 edition) and the patient's asthma symptoms must be confirmed as well-controlled. (5) Receiving treatment with dual-mite (Dermatophagoides pteronyssinus and farinae) subcutaneous immunotherapy (SCIT). Exclusion Criteria: * (1) Participants and/or their parents/legal guardians are judged by the investigator to be unable to fully understand the study requirements, or to adhere to long-term treatment and identify adverse reactions (including but not limited to conditions such as cognitive impairment or mental illness); (2) Children with severe or uncontrolled asthma (FEV1 \< 70% of predicted value) or with irreversible airflow obstruction; (3) Children using beta-blockers or angiotensin-converting enzyme inhibitors (ACEI); (4) Children with severe autoimmune diseases or immunodeficiencies, including AIDS, inflammatory bowel disease, etc., as well as those currently using immunosuppressants; (5) Children with severe cardiovascular diseases or malignant tumors; (6) Children with incomplete clinical data.

Inclusion Criteria: * Aged 18 to 85 years. Scheduled for elective cardiac surgery (e.g., CABG, valve replacement/repair). NYHA cardiac function class I-III. Willing and able to provide informed consent. Expected surgery duration ≥ 2 hours. Exclusion Criteria: * Preoperative MMSE score \< 24; severe communication barriers. History of diagnosed delirium, dementia, Parkinson's disease, schizophrenia, bipolar disorder, major depressive disorder, or long-term use of psychotropic drugs. Skin lesions, infection, or deformity of bilateral ears; history of ear surgery or nerve injury; allergy to electrode materials. Severe arrhythmia; implanted electronic devices (e.g., pacemaker, ICD). Participation in another interventional trial within 3 months. Other conditions deemed unsuitable by investigators.

Inclusion Criteria: \- Healthy pregnant women, patients with miscarriage, etc. Exclusion Criteria: * Heart disease, infections, etc. in pregnant women Uncooperative patients

Inclusion Criteria: * Histologically confirmed primary breast cancer * Stage I-III non-metastatic breast cancer following lumpectomy or mastectomy * Completed adjuvant chemotherapy (with or without radiotherapy) * Age ≥ 18 years * Able to understand and follow the study protocol * Willingness to attend facility-based exercise training. Exclusion Criteria: * Metastatic (Stage IV) breast cancer * Morbid obesity (BMI \> 40 kg/m²) * Uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 99 mmHg) * Presence of implantable medical devices (e.g., pacemakers, nerve stimulators) * Presence of metallic surgical implants (e.g., total hip or knee replacements) that interfere with assessment devices * Contraindications for resistance training (e.g., acute infectious disease, severe cardiac disease, severe respiratory insufficiency) * Concurrent malignant diseases * Current participation in intense systematic exercise training (defined as at least 1 hour, twice per week) * Previous participation in an exercise intervention clinical trial.

Participant Inclusion Criteria: * Adults 65 years and older at time of consent * Actively receiving care at a UNC Health or UNC Physicians Network clinic (defined as 2 or more visits in primary care, family medicine, internal medicine, geriatrics, or endocrinology clinics within the past 365 days). Locality for care is defined as receiving care within a 90-mile radius of UNC Main Hospital on Manning Drive in Chapel Hill, NC. * Using any insulin * No continuous glucose monitor (CGM) use within the previous 365 days * Willing to use a smartphone to access glucose readings using CGM phone app * Fluent in English Participant Exclusion Criteria: * Clinical diagnosis of dementia, assessed through chart review and self-report on screening visit (cognitive impairment that is mild and not considered sufficient for diagnosis of dementia is acceptable) * Currently receiving dialysis, assessed through chart review and self-report on screening visit * Extreme visual or hearing impairment that would impair ability to use real-time CGM or attend and participate in an in-person or virtual group intervention session, assessed at screening visit * The presence of a significant medical or psychiatric condition or use of a medication that in the judgment of the investigator may affect completion of any aspect of the protocol, or is likely to be associated with life expectancy of \<1 year, assessed at screening visit * Unavailable for 6-week study duration (such as planned surgery or procedure, planned vacation, etc.) or unwilling to comply with study procedures * Not fluent in English * Unable to consent to recording of sessions Care Partner Inclusion Criteria: * Live in the same household as the study participant * Age 18 years or older * Fluent in English * Be willing to attend sessions alongside the study participant and learn how they can better support their partner participant to manage diabetes * Consent to recording of sessions

Inclusion Criteria: * Age \>18 years; * Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer; * Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion; * Patients with ovarian carcinomas; * Patients with metastatic melanoma; * Patients with stage IIB and IIIA non-small cell lung cancer. Exclusion Criteria: * Age \<18 years; * Unwillingness or inability to give informed consent

Inclusion Criteria: * Receiving prenatal care at participating obstetric practice * Endorsed mild to moderate anxiety (GAD-7 score 5-15) * Currently pregnant (gestational age \<32) * Started Reaching Calm digital intervention, if in intervention group Exclusion Criteria: * Not pregnant * Unable to participate in 60-minute interview * Unwilling to be audio recorded * GAD-7 \<5, or GAD-7≥15 * Adults unable to consent (adults lacking capacity) * Individuals who are not yet adults (infants, children, teenagers) * Prisoners * Non-English-speaking

Inclusion Criteria: * Female patients aged 18 to 70 years, inclusive. * Histologically confirmed, treatment-naïve, early-stage triple-negative breast cancer (TNBC), defined as estrogen receptor (ER) and progesterone receptor (PR) expression \<1% by immunohistochemistry (IHC), and human epidermal growth factor receptor 2 (HER2)-negative (IHC 0/1+ or IHC 2+ with negative in situ hybridization confirmation) per current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. * Clinical stage T1cN1-2 or T2-4N0-2 according to the American Joint Committee on Cancer (AJCC) staging system, 8th edition. * At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic, hepatic, renal, and cardiac function within 14 days prior to enrollment: * Hematologic: Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L; platelet count ≥100 × 10⁹/L; hemoglobin ≥90 g/L (without transfusion or growth factor support within 14 days). * Hepatic: Total bilirubin ≤1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN. * Renal: Serum creatinine and blood urea nitrogen (BUN) ≤1.5 × ULN. * Cardiac: Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiogram; corrected QT interval (QTc) \<470 ms on 12-lead electrocardiogram (ECG). * Willingness to provide archival or fresh tumor tissue sample for programmed death-ligand 1 (PD-L1) biomarker analysis using the 22C3 pharmDx assay. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Evidence of metastatic (Stage IV) disease or bilateral breast cancer at diagnosis. * Prior systemic anticancer therapy (including chemotherapy, endocrine therapy, immunotherapy, or biological therapy) for any malignancy within 4 weeks before the first dose of study treatment. * Diagnosis of any other malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer, basal cell carcinoma, or carcinoma in situ of the cervix. * Known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV-DNA ≥500 IU/mL), or hepatitis C virus (detectable HCV-RNA). * Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring systemic antibiotic therapy within 2 weeks, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements. * History of allogeneic hematopoietic stem cell or solid organ transplantation. * Pregnant or lactating women, or women of childbearing potential who are unwilling to use a highly effective method of contraception during the treatment period and for at least 7 months after the last dose. * Known hypersensitivity to any component of serplulimab or SHR-A1811. * Any condition that, in the opinion of the investigator, would compromise patient safety or interfere with the completion of the study procedures.

Inclusion Criteria: * Female gender * Being a primary caregiver of an individual with special needs * Aged between 18 and 55 years * Caring for an individual who has a valid Special Needs Assessment Report for Children (ÇÖZGER) or a Health Board Report for Adults (ESKR) * Ability to communicate in Turkish * Being literate * Willingness to participate in the study and provide informed consent Exclusion Criteria: * Pregnancy * Presence of a neurological condition (e.g., epilepsy, acute cerebrovascular event) * Presence of tumors or metastatic disease * Unwillingness to participate in the study * Inability to cooperate with study procedures

Inclusion Criteria: 1. High-risk prediabetes ("at high risk for type 2 diabetes") defined by meeting the following 2 prediabetes criteria established by the American Diabetes Association (ADA) in the 2010 clinical practice guidelines: 1. Fasting plasma glucose (FPG) 100-125 mg/dL, inclusive 2. Hemoglobin A1c (HbA1c) 5.7-6.4%, inclusive 2. Age 30-74 years, inclusive 3. Body Mass Index ≥ 23.0 and ≤ 35.0 kg/m2 4. Provision of signed and dated written informed consent prior to any study procedures. Exclusion Criteria: 5. History of diabetes (ICD10 diabetes code E08.X through E13.X) or meeting a diabetes glycemic criterion at screening, as defined by the ADA guidelines (FPG ≥ 126 mg/dL or HbA1c ≥ 6.5%). 6. History (past 2 years) of hyperparathyroidism, symptomatic or asymptomatic (i.e., radiographic) nephrolithiasis or hypercalcemia. 7. Any medical condition (past 2 years) that in the opinion of the site investigator may increase risk for nephrolithiasis or hypercalcemia during the trial (e.g., sarcoidosis). 8. If older than 70 years, history (past 1 year) of a fall. 9. Use of tanning devices within 12 weeks of the baseline visit and unwilling to stop use of tanning devices for the duration of the study. Medications and Supplements 10. Use (past 6 months) of hypoglycemic pharmacotherapy (oral or injectable medication approved by the FDA for type 2 diabetes) for any condition (e.g., prediabetes, diabetes, polycystic ovarian syndrome, MASLD, sleep apnea) or any other medication that may affect glycemia (e.g., hydroxychloroquine) 11. Current use of medications approved by the FDA for weight management (e.g., incretin receptor agonists) or planned use during the study. 12. Use of supplements containing vitamin D at total doses higher than 1000 IU/day within 8 weeks of the baseline visit and unwillingness to limit vitamin D supplementation dosage to no higher than 1000 IU/day during the study. Because supplements vary widely in vitamin D content (e.g., may include cod liver or cod liver oi), participants will bring all supplements to the site for a review by the research team. 13. Use of supplements containing calcium at total doses higher than 600 mg/day within 1 week of the baseline visit and unwillingness to limit calcium supplementation dosage to no higher than 600 mg/day during the study. 14. Current use of medications or conditions (e.g., untreated celiac disease) that would interfere with the absorption or metabolism of vitamin D. 15. Use of an anticonvulsant drug started within 6 months of screening. Stable regimen of anticonvulsants is allowed. 16. History of intolerance to vitamin D supplements, allergic to any content of the study drug or unwilling to take vitamin D supplements (e.g., someone who eats a vegan diet and would object to the cholecalciferol ingredient which is produced from cholesterol extracted from sheep wool harvested from healthy living sheep). Other Medical History 17. Severe symptomatic cardiovascular disease based on history (unstable angina, dyspnea on exertion, paroxysmal nocturnal dyspnea, arrhythmia, congestive heart failure NYHA class II or higher, claudication) 18. History (past 1 year) of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft. 19. History (past 1 year) of cerebrovascular disease (stroke, transient ischemic attack). 20. Any type of cancer (past 5 years) except for basal cell skin cancer. Prostate cancer (for men over age 55) or well-differentiated thyroid cancer not expected to require treatment (except for suppression with thyroid hormone) over the next 3 years, are not exclusions. People with history of squamous cell cancer of the skin, which was completely excised and with no evidence of metastases, are eligible. 21. History (past 6 months) of treatment with oral (for \> 7 days) or intravenous glucocorticoids or disease likely to require oral or intravenous glucocorticoid therapy during the study. Inhaled glucocorticoid use is not an exclusion. Epidural or intra-articular glucocorticoid injections are not exclusions, but study visits need to be conducted at least two weeks after the injection. Persons with adrenal insufficiency treated with physiologic doses of glucocorticoids who are otherwise stable are not excluded. 22. History (past 1 year) of substance abuse or unstable psychiatric disorder that in the opinion of the site investigator would impede competence or adherence with study procedures or hinder completion of the study or increase risk. 23. History of bariatric surgery (e.g., Roux-en-Y gastric bypass, gastric sleeve) or planned bariatric surgery in the next 2 years. 24. Extreme (over 18 hours) intermittent fasting diets because prolonged fasting downregulates CYP2R1 activity. 25. A life-threatening event within 30 days of screening or currently planned major surgery. 26. Any other active medical condition (including but not limited to liver disease, wasting illness, HIV, tuberculosis, oxygen-dependent chronic obstructive pulmonary disease, organ transplant, Cushing's syndrome) that in the opinion of the site investigators would interfere with the study objectives, impede competence or adherence with study procedures or increase risk. 27. Uncontrolled hypertension (systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 100 mm Hg). 28. Poor venous access. Laboratory Evaluation 29. Serum liver transaminase higher than 3 times the normal range for the clinical site's laboratory, within 18 months of screening. 30. Anemia (hematocrit \< 32 for women, \< 36 for men), whole blood transfusion (within 18 months of screening) or chronic requirement, whole blood donation (within 3 months of screening) or other condition (hemolysis, hemoglobinopathy) rendering HbA1c results unreliable as indicator of chronic glycemia. Participants who donate platelets are not excluded. 31. Low platelet count (\< 100,000) within 18 months of screening. 32. Chronic kidney disease, defined as estimated glomerular filtration rate \[GFR\] \< 50 mL/min per 1.73 m2 from creatinine level and GFR calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations that omit race within 18 months of screening. 33. Hypercalcemia, defined as serum calcium concentration ≥ upper limit of normal within 18 months of screening. 34. Hypercalciuria, defined as spot urine (morning void) calcium-creatinine ratio \> 0.275 within 18 months of screening. 35. Baseline serum 25(OH)D level greater than 100 ng/mL. Other 36. Participation (within 30 days of screening) in another interventional research study, and unwillingness to refrain from participating in another intervention study during the study. 37. Previous randomization in the study. Participants who did not qualify after screening may be screened again if the prior reason for exclusion has been addressed (e.g., high blood pressure is treated). 38. Any other reason that in the opinion of the site investigator would interfere with the study objectives, impede adherence with study procedures or hinder completion of the study or increase risk. Women only 39. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to become pregnant in the next 2 years. History of gestational diabetes is not an exclusion criterion. 40. Currently breastfeeding. 41. Use of oral contraceptives or menopausal hormone therapy started within 3 months of baseline. . Continuous Glucose Monitoring specific 42. Regular use of personal CGM and unwillingness to refrain from using personal CGM for the duration of the study. 43. Use of hydroxyurea or regular use of high doses of acetaminophen (may impact CGM). 44. Extensive skin changes (e.g., skin breakdown, rash) making CGM sensor use problematic. 45. Significant skin sensitivity to adhesive (making CGM sensor unfeasible).

Inclusion Criteria: 1. Female patients aged ≥ 18 years; 2. Histologically confirmed HER2-negative invasive breast cancer (defined as: HER2 0 or 1+, or HER2 2+ with negative FISH result indicating no amplification); 3. Breast cancer with liver metastasis; 4. Patients who have received and failed ≥ 1 line of systemic therapy after diagnosis of recurrent or metastatic breast cancer, with documented disease progression: For HR+/HER2- advanced breast cancer: prior CDK4/6 inhibitor therapy in the advanced setting; For HR-/HER2- advanced breast cancer: at least one line of chemotherapy in the advanced setting; 5)At least one measurable lesion per RECIST 1.1 (not previously irradiated) other than the ablation target lesions; 6)Intrahepatic metastatic lesions: number ≤ 10, maximum diameter ≤ 4 cm, no vascular or bile duct invasion; 7)Adequate organ function, meeting the following criteria: 1. Laboratory hematology: HB ≥ 90 g/L (without transfusion within 14 days); ANC ≥ 1.5×10⁹/L; PLT ≥ 75×10⁹/L; 2. Laboratory biochemistry: TBIL ≤ 1.5×ULN (upper limit of normal); ALT and AST ≤ 5×ULN; 8) Expected survival ≥ 12 weeks; 9)Female subjects of childbearing potential must use a medically accepted contraceptive method during study treatment and for at least 3 months after the last dose of study drug. 10)Subjects have voluntarily agreed to participate in this study, signed the informed consent form, are compliant, and willing to comply with follow-up requirements. Exclusion Criteria: 1. Uncontrolled central nervous system (CNS) metastases, defined as symptomatic metastases or those requiring glucocorticoids or mannitol for symptom control. 2. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina pectoris, myocardial infarction within the past 6 months, or ventricular arrhythmia. 3. Received radiotherapy or surgical treatment for advanced HER2-negative breast cancer within 1 week prior to the first study drug administration or study procedure. 4. Pregnant or lactating patients. 5. Malignancy diagnosed within the past 3 years, except for cured basal cell carcinoma of the skin and carcinoma in situ of the uterine cervix. 6. Significant comorbidities, including psychiatric disorders that, in the investigator's judgment, would adversely affect the patient's participation in the study. 7. History of gastrointestinal bleeding or definite gastrointestinal bleeding tendency within the previous 6 months, including esophageal varices at risk of bleeding, active local ulcerative lesions, or stool occult blood ≥ ++. Patients with stool occult blood (+) must undergo gastroscopy. 8. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to study enrollment. 9. Urinalysis showing urine protein ≥ ++ or confirmed 24-hour urinary protein \> 1.0 g. 10. Hypertension that cannot be controlled within the normal range by antihypertensive therapy (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg). 11. Patients with allergic constitution, known hypersensitivity to any component of the study drugs, or hypersensitivity to other monoclonal antibodies. 12. Pre-existing thyroid dysfunction. 13. Any other conditions in which the investigator deems the patient unsuitable for participation in this study.

Inclusion Criteria: * Men or women aged 18 and over * Biopsy proven invasive triple negative breast cancer (defined here as estrogen receptor \<10%, progesterone receptor \<10%, human epidermal growth factor receptor 2 (HER2) negative status, with HER2 status being defined as per ASCO/CAP guidelines) * T2-4/N0 (\>2 cm primary breast cancer as assessed clinically or on imaging in the absence of nodal involvement) OR T1c-4/N1-3 disease (\>10mm with fine needle aspirate or core biopsy confirming nodal involvement is required) * Residual disease (RCB 2 or 3) on surgical specimen after completion of neoadjuvant chemo(-immuno)therapy Exclusion Criteria: * Inability to provide informed consent. Participants who require translators are allowed to enroll * Prior history of invasive breast cancer -Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the detection of BC recurrence on a liquid biopsy (patients with a history of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma-in-situ of cervix are permitted to participate)- * Pregnant patients are not permitted * Creatinine clearance \<45 mL/min using the Cockcroft-Gault equation.